These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 20126838)
21. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Toth PP Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814 [TBL] [Abstract][Full Text] [Related]
22. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Wouter Jukema J; Collet JP; De Luca L Curr Med Res Opin; 2012 Feb; 28(2):203-11. PubMed ID: 22181345 [TBL] [Abstract][Full Text] [Related]
30. Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens? Serebruany VL Fundam Clin Pharmacol; 2009 Aug; 23(4):411-7. PubMed ID: 19500152 [TBL] [Abstract][Full Text] [Related]
31. Prasugrel: a critical comparison with clopidogrel. Reinhart KM; White CM; Baker WL Pharmacotherapy; 2009 Dec; 29(12):1441-51. PubMed ID: 19947804 [TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD; Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740 [TBL] [Abstract][Full Text] [Related]
33. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. Baker WL; White CM Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817 [TBL] [Abstract][Full Text] [Related]
35. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Silvain J; Cayla G; Hulot JS; Finzi J; Kerneis M; O'Connor SA; Bellemain-Appaix A; Barthélémy O; Beygui F; Collet JP; Montalescot G Eur Heart J; 2012 May; 33(10):1241-9. PubMed ID: 22067090 [TBL] [Abstract][Full Text] [Related]
36. Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. Salisbury AC; Wang K; Cohen DJ; Li Y; Jones PG; Spertus JA Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):27-34. PubMed ID: 23212457 [TBL] [Abstract][Full Text] [Related]
37. Prasugrel development - claims and achievements. Serebruany V; Shalito I; Kopyleva O Thromb Haemost; 2009 Jan; 101(1):14-22. PubMed ID: 19132184 [TBL] [Abstract][Full Text] [Related]
39. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Jakubowski JA; Winters KJ; Naganuma H; Wallentin L Cardiovasc Drug Rev; 2007; 25(4):357-74. PubMed ID: 18078435 [TBL] [Abstract][Full Text] [Related]